4.7 Article

Oxo-heterocyclic fused naphthalimides as antitumor agents: Synthesis and biological evaluation

期刊

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
卷 62, 期 -, 页码 130-138

出版社

ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2012.12.039

关键词

Oxo-heterocyclic; Naphthalimides; Antitumor agents; Topo I; Topo II; DNA intercalation

资金

  1. National Basic Research Program of China (973 Program) [2010CB126100]
  2. National High Technology Research and Development Program of China (863 Program) [2011AA10A207]
  3. China 111 Project [B07023]
  4. Fundamental Research Funds for the Central Universities
  5. Shanghai Committee of Science and Technology [11DZ2260600]

向作者/读者索取更多资源

Three series of novel oxo-heterocyclic fused naphthalimide derivatives (8a-8f, 13a-13d, 17a-17d) were prepared. The newly-synthesized compounds, and their thio-heterocyclic fused analogs (1a-1c, 2a-2d, 3a-3c) exhibited potent antiproliferative activity correlated well with their structure. Further research demonstrated that all the representative compounds 13a, 2a and 17a, 3a showed strong inhibition activity to topo II similarly with amonafide, and also potent topo I inhibition activity, which was seldom reported before for naphthalimide derivatives. Preliminary exploration proved their DNA sequence preference. In all, dual topo I/topo II inhibition and DNA sequence preference might contribute to enhancing tumor selectivity and overcoming drug resistance. (C) 2013 Elsevier Masson SAS. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据